Evidence map›Paper›PMID 41627430›Full record

ArticleChirurgie (Heidelberg, Germany)2026

[Adrenocortical carcinoma (ACC): current surgical treatment strategies].

Detlef K Bartsch

Abstract readEnglish Abstract
In one paragraph

Article in Chirurgie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Detlef K BartschKlinik für Visceral‑, Thorax- und Gefäßchirurgie, Universitätsklinikum Marburg, Baldingerstraße, 35043, Marburg, Deutschland. bartsch@med.uni-marburg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) is among the rarest solid malignancies, but is characterized by pronounced biological aggressiveness and a high risk for recurrence. Complete tumor resection (R0) remains the only potentially curative treatment and is the primary determinant of long-term survival. Given the functional heterogeneity of ACC and the frequent presence of hypercortisolism or androgen excess, preoperative evaluation and perioperative management require close interdisciplinary management. Open adrenalectomy continues to be regarded as the gold standard, whereas minimally invasive techniques may be considered in strictly selected cases and within high-volume expert centers. The relevance of systematic lymphadenectomy is increasingly recognized, although its optimal extent remains a matter of debate. Postoperatively, adjuvant therapy is tailored according to individual risk profiles, with mitotane indicated for patients at intermediate or high risk of recurrence. Recurrence is common and should be managed surgically whenever technically feasible. In metastatic disease, multimodal treatment strategies-integrating surgical, interventional radiologic, and systemic approaches-play a central role. Although the overall prognosis remains limited, surgical expertise and treatment within specialized centers are the key for improved patient outcomes.

Indexed as

Adrenal Cortex NeoplasmsAdrenalectomyAdrenocortical CarcinomaCombined Modality TherapyHumansLymph Node ExcisionMinimally Invasive Surgical ProceduresMitotaneNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRobotic Surgical ProceduresMitotaneAdrenal cortexAdrenalectomyAdrenocortical cancerLymph node excisionRobotic surgical procedures

Identifiers

PMID41627430
PMCPMC13106234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.